Budesonide-based triple therapy is effective in reducing the risk of severe pneumonia and death in COPD patients, especially in those with higher blood eosinophil count, reveals a recent research. The findings of the study, published in the Journal of Chronic Obstructive Pulmonary Disease, used data from 29,716 new users of fluticasone-based triple therapy and 9646 new users of budesonide-based triple therapy, from the Clinical Practice Research Datalink. The research found that the incidence of a moderate or severe exacerbation and all-case death incidence was lower with budesonide-based triple therapy.